# Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

> **NCT07202052** · PHASE2,PHASE3 · RECRUITING · sponsor: **Monash University** · enrollment: 900 (estimated)

## Conditions studied

- Myeloma
- Non-Hodgkin's Lymphoma
- Leukemia

## Interventions

- **BIOLOGICAL:** Intravenous immunoglobulin
- **DRUG:** Trimethoprim / Sulfamethoxazole
- **DRUG:** Amoxicillin clavulanic acid
- **BIOLOGICAL:** Intravenous immunoglobulin (IVIG)

## Key facts

- **NCT ID:** NCT07202052
- **Lead sponsor:** Monash University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07202052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07202052, "Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07202052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*